Mark Hartmann
Overview
Explore the profile of Mark Hartmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mancarella D, Ellinghaus H, Sigismondo G, Veselinov O, Kuhn A, Goyal A, et al.
Int J Cancer
. 2024 Feb;
154(12):2106-2120.
PMID: 38353495
Mutations in histone H3.3-encoding genes causing mutant histone tails are associated with specific cancers such as pediatric glioblastomas (H3.3-G34R/V) and giant cell tumor of the bone (H3.3-G34W). The mechanisms by...
2.
Schopf J, Uhrig S, Heilig C, Lee K, Walther T, Carazzato A, et al.
Nat Commun
. 2024 Jan;
15(1):51.
PMID: 38168093
Linking clinical multi-omics with mechanistic studies may improve the understanding of rare cancers. We leverage two precision oncology programs to investigate rhabdomyosarcoma with FUS/EWSR1-TFCP2 fusions, an orphan malignancy without effective...
3.
Hey J, Halperin C, Hartmann M, Mayer S, Schonung M, Lipka D, et al.
Int J Cancer
. 2022 Nov;
152(6):1226-1242.
PMID: 36408934
The accumulation of myeloid cells, particularly tumor-associated macrophages (TAMs), characterizes the tumor microenvironment (TME) of many solid cancers, including breast cancer. Compared to healthy tissue-resident macrophages, TAMs acquire distinct transcriptomes...
4.
Schonung M, Hartmann M, Kramer S, Stable S, Hakobyan M, Kleinert E, et al.
Exp Hematol
. 2022 Nov;
117:24-42.e7.
PMID: 36368558
Differentiation of hematopoietic stem and progenitor cells to terminally differentiated immune cells is accompanied by large-scale remodeling of the DNA methylation landscape. Although significant insights into the molecular mechanisms of...
5.
Zanetti C, Kumar R, Ender J, Godavarthy P, Hartmann M, Hey J, et al.
Blood
. 2021 Aug;
138(19):1870-1884.
PMID: 34424946
B-cell acute lymphoblastic leukemia (B-ALL) occurs most commonly in children, whereas chronic myeloid leukemia is more frequent in adults. The myeloid bias of hematopoiesis in elderly individuals has been considered...
6.
Schonung M, Meyer J, Nollke P, Olshen A, Hartmann M, Murakami N, et al.
Clin Cancer Res
. 2020 Nov;
27(1):158-168.
PMID: 33139265
Purpose: Known clinical and genetic markers have limitations in predicting disease course and outcome in juvenile myelomonocytic leukemia (JMML). DNA methylation patterns in JMML have correlated with outcome across multiple...
7.
Lutsik P, Baude A, Mancarella D, Oz S, Kuhn A, Toth R, et al.
Nat Commun
. 2020 Oct;
11(1):5414.
PMID: 33110075
The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration. We...
8.
Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia
Krombholz C, Gallego-Villar L, Sahoo S, Panda P, Wlodarski M, Aumann K, et al.
Leukemia
. 2019 Jan;
33(7):1805-1810.
PMID: 30679798
No abstract available.
9.
Daskalakis M, Brocks D, Sheng Y, Islam M, Ressnerova A, Assenov Y, et al.
Cell Cycle
. 2018 Apr;
17(7):811-822.
PMID: 29633898
Inhibitors of DNA methyltransferases (DNMTis) or histone deacetylases (HDACis) are epigenetic drugs which are investigated since decades. Several have been approved and are applied in the treatment of hematopoietic and...
10.
Lipka D, Witte T, Toth R, Yang J, Wiesenfarth M, Nollke P, et al.
Nat Commun
. 2017 Dec;
8(1):2126.
PMID: 29259247
Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative disorder of early childhood characterized by mutations activating RAS signaling. Established clinical and genetic markers fail to fully recapitulate the clinical and...